Medical Equipment

Neuromuscular Disorders Market Forecast 2026–2035 Highlighting Expansion Opportunities

April 9, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Neuromuscular Disorders Market Evolve From 2026 To 2030?

The neuromuscular disorders market size has experienced strong growth in recent years. It is projected to expand from $8.31 billion in 2025 to $8.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This market’s historical growth can be attributed to factors such as the increasing prevalence of genetic neuromuscular conditions, rising awareness concerning early diagnosis and treatment options, a growing demand for effective therapies for rare disorders, an increase in research initiatives related to muscular dystrophy and ALS, and the rising adoption of advanced diagnostic technologies.

The neuromuscular disorders market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $12.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This projected increase during the forecast period can be attributed to several factors, including the increasing activities of patient advocacy and support groups, the rising demand for biologics and gene therapies, enhanced awareness of neuromuscular conditions in pediatric populations, growing governmental efforts for managing rare diseases, and a greater focus on home-based care and rehabilitation services. Key developments expected in this period encompass progress in gene-editing technologies for targeted therapies, novel approaches in RNA-based treatment platforms, the incorporation of artificial intelligence for more rapid neuromuscular diagnoses, breakthroughs in stem-cell-based regenerative treatments, and advancements in wearable devices for ongoing patient observation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30678&type=smp

What Key Drivers Are Influencing The Growth Of The Neuromuscular Disorders Market?

The increasing need for personalized medicine is anticipated to fuel the expansion of the neuromuscular disorders market in the future. This medical strategy customizes therapies for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices, to maximize treatment effectiveness and enhance overall patient care. The surge in demand for personalized medicine stems from progress in genomic technologies, facilitating the accurate detection of genetic variations and the development of customized treatments. It improves the management of neuromuscular disorders through the customization of treatments according to a patient’s specific genetic, molecular, and physiological characteristics. This approach leads to better patient results by allowing for focused therapies, enhancing effectiveness, and reducing unwanted side effects. As an illustration, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) sanctioned 26 novel personalized medicines in 2023, marking a considerable rise from the 12 approvals observed in 2022. Consequently, the growing requirement for personalized medicine is a key driver for the expansion of the neuromuscular disorders market.

Which Segment Areas Are Covered In The Neuromuscular Disorders Market Analysis?

The neuromuscular disorders market covered in this report is segmented –

1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies

2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices

3) By Route of Administration: Oral, Injectable, Other Route of Administrations

4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care

Subsegments:

1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)

2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS

3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations

4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG

5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy

What Key Developments And Trends Are Impacting The Neuromuscular Disorders Market?

Major companies within the neuromuscular disorders market are increasingly focusing on the development of advanced treatments, such as gene replacement therapies, to address the underlying genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy encompasses engineered biological products designed to deliver functional copies of defective genes, aiming to restore or enhance muscle function in patients with inherited neuromuscular conditions, thereby offering a potential one-time treatment that diminishes the necessity for long-term chronic therapy. A notable example occurred in November 2025, when Novartis, a Switzerland-based pharmaceuticals company, obtained US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve). This therapy stands as the first and only gene replacement therapy sanctioned for the treatment of children two years of age and older, teens, and adults diagnosed with spinal muscular atrophy (SMA) who possess a confirmed mutation in the survival motor neurone 1 (SMN1) gene. Itvisma is specifically formulated to treat the genetic root cause of SMA with a single, fixed dosage that requires no adjustments based on body weight or age, and it can improve motor function by substituting the SMN1 gene, potentially reducing the need for long-term medication used alongside other current treatments for this patient demographic.

Which Leading Firms Are Contributing To The Growth Of The Neuromuscular Disorders Market?

Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.

Read the full neuromuscular disorders market report here:

https://www.thebusinessresearchcompany.com/report/neuromuscular-disorders-market-report

Which Regions Are Poised For Strategic Growth In The Neuromuscular Disorders Market?

North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuromuscular Disorders Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30678&type=smp

Browse Through More Reports Similar to the Global Neuromuscular Disorders Market 2026, By The Business Research Company

Muscle Spasticity Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report

Muscle Wasting Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

neurological disorder drugs global market report

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795